NASDAQ$MBRX
Moleculin Biotech Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended March 31, 2021, and provided a program update.
Moleculin Biotech reported a net loss of $4.4 million for the first quarter of 2021, with research and development expenses increasing due to expanded clinical trial activity and manufacturing costs. The company's cash position was significantly strengthened, ending the quarter with approximately $86.3 million.
- Granted Rare Pediatric Disease Designation (RPD) from the FDA to WP1066 for ependymoma.
- Engaged IQVIA Biotech to manage potential clinical trials of WP1122 for COVID-19 treatment.
- Received Fast Track Designation from the FDA for Annamycin for soft tissue sarcoma (STS) lung metastases.
- Closed a public offering for gross proceeds of approximately $78.0 million, strengthening the financial position.
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Forward guidance
Moleculin anticipates several key clinical and regulatory milestones over the next 18 months, supported by a strengthened financial position that extends the cash runway through 2023. The company plans to advance its portfolio of drug candidates across multiple oncology indications and viruses, with the potential for up to seven clinical trials this year.
Tailwinds
- Anticipated topline results from the ongoing Phase 1/2 study for Annamycin in AML in 2H 2021.
- Planned commencement of a Phase 1/2 study in Europe for Annamycin + Ara-C in AML in 2H 2021.
- Expected commencement of a Phase 1b/2 clinical trial of Annamycin for STS lung metastases in the U.S. in 2H 2021.
- Planned facilitation of a Phase 1/2 study of WP1066 + radiation for GBM in 2H 2021.
- Aimed launch of a Phase 2 study of WP1066 for pediatric brain tumors, including DIPG, in 1H 2022.
Headwinds
- Uncertainty regarding the success of investigator-funded trials.
- Dependence on finding collaboration partners for WP1220 development.
- Risk that preclinical performance of WP1122 may not translate into improved clinical outcomes.
- Potential delays in initiating Phase 1a/1b study of WP1122 for COVID-19.
- Uncertainty regarding the ability to file an IND for WP1122 in antiviral indications by 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2021
-1.3%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-5.3%
Avg return
30 days after
33%
13 / 40 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +2.8% | +9.8% | — | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.6% | +13.2% | |
| Q4 2020 | -1.5% | -6.6% | -99.8% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro